ESMO is pleased to share the ESMO Presidential Election election results:
G Curigliano MD PhD (Italy) will be the ESMO President 2027-2028 and will join the ESMO Executive Board on 1 January 2025 as President-Elect.
👉ow.ly/Si8g50SgGlQ

New article in press: Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study
annalsofoncology.org/article/S0923-…

We are thrilled to share that Annals of Oncology has achieved an impressive new CiteScore of 63.9!

June issue of Ann Oncol now online
tinyurl.com/36btwnmu
⏺️ESMO CPG update on 1st line therapy in adv urothelial carcinoma
⏺️review on Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer
⏺️ 5-year results from CheckMate 040 trial in HCC
And more

Bladder cancer highlight #ASCO24 Disitimab Vedotin with toripalimab show pCR rate >60% with no surgery cancelled due to AEs. Immature 1yr DFS >80% despite 60% T3 or more. The data are good enough for R3 studies. Although 6 more mos of follow up would be reassuring.

Prostate cancer highlight #ASCO24 was the clinical/genetic ctDNA based prognostic model which predicted OS in mCRPC. ctDNA levels, particularly those to AR genes, ⬆️accuracy compared to clinical markers alone. Integrating real time biology & tumor stage is an important next step.

Renal cancer highlight #ASCO24 was the potentially predictive & prognostic KIM1 biomarker in adjuvant kidney cancer. It builds on previous data with Ipi/nivo. Multiple methods to define positivity (assay/level) is problematic. Concordance is needed before validation.

Preliminary data from PASS-01 demonstrate feasibility and early signs of efficacy integrating molecular profiling to allocate first-line treatment in metastatic #PancreaticCancer . #pancsm #PrecisionMedicine #ASCO24

New📢Primary Central Nervous System #Lymphomas : European Hematology Association–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Covering clinical, imaging & pathological diagnosis, staging & risk assessment, tx, & algorithms for first-line & salvage treatments.…

Novel phase 2 immune therapy/chemotherapy penile cancer trial has reported a response rate of 40%. The trials are hard and potentially practice changing. There won't be randomised trials. IIT from Brazil - congratulations #ASCO24

Neoadjuvant bladder cancer data #ASCO24 for toripalimab & disitimab vedotin in muscle invasive bladder cancer (n=47). pCR⬆️63%. 14% G3/4 AEs. All surgeries occurred. 6 cycles of treatment. The 1st MMAE/IO neoadjuvant combo data look ☑️☑️. Randomised trials needed.

initial data from SUC-SARC032 trial presented by David Kirsch, MD, PhD radiotherapy & surgery +/- pembrolizumab in patients with resectable stage III #sarcoma (UPS or LPS)
🔷2yr DFS 53% vs 70%
🔷no statistically significant difference in LRFS & DDFS
🔷OS data immature
#ASCO24

Vimseltinib -oral CSF1R inhibitor is effective in patients with tenosynovial giant cell tumor (TGCT) - results of phase III trial presented by William Tap at #ASCO24
🔷ORR at 25 weeks 40% vs 0% (placebo)
🔷significant improvement in functional health and #QOL
#sarcoma

ctDNA results of chemo vs pembro in 1st line mUC (KN361) #ASCO24 . 90% of patients are ctDNA +ve. Better outcomes for pembro occur with lower ctDNA baseline levels. ctDNA clearance occurs in chemo=41%, pembro=11%. But reductions more clinically meaningful with pembro.

PRO data from EV302 (EVP vs chemo) in 1st line UC assesses pain & global health scores, many of which are similar in the 2 groups. Exploratory differences favoring EVP identified particularly in those w/ symptoms. Novel methods were used but PRO assessment isn't perfect #ASCO24

CLEAR/KN426/IM151 biomarker data shows consistency & design issue (VEGF in both). No subgroup points to VEGF>VEGF/TKI. Even T signatures struggled for IO in CLEAR. DNA analysis wasn't useful. Sunitinib doing poorly in angio/low is strongest signal. KIM1 seems real deal #ASCO24